Posted by Michael Wonder on 30 Jul 2021
Erytech granted U.S. FDA fast track designation for Eryaspase in hypersensitive ALL
29 July 2021 - Fast track designation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginase.
Erytech Pharma announced today that the U.S. FDA has granted eryaspase fast track designation for the treatment of acute lymphocytic leukemia patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.
